Case analysis of a patient with NTRK gene fusion-positive colorectal cancer presenting with short-lived response
This case report describes a patient with NTRK1 fusion-positive colorectal cancer who experienced a short-lived response to larotrectinib, highlighting the need for further investigation into resistance mechanisms such as secondary mutations or alternative pathway activation to guide subsequent treatment strategies.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Imagine the human body as a bustling city where every cell is a building following strict instructions on when to grow, when to stop, and when to retire. Usually, these instructions are like a well-organized library, but sometimes, a typo in the blueprint causes a building to ignore the "stop" signs and grow uncontrollably, turning into a tumor. In the world of cancer research, scientists are constantly looking for these specific typos to find the right key to lock the door. One such key involves a family of proteins called NTRK. Think of NTRK as a master switch that controls cell growth. Normally, this switch is turned off until it receives a specific signal. But in some rare cancers, a piece of DNA gets swapped with a piece from another gene, creating a "fusion." This fusion acts like a broken switch that is stuck in the "ON" position, forcing the cell to grow forever. While this broken switch is a common cause of cancer in some rare types of tumors, it is a very rare guest in colorectal cancer (cancer of the colon or rectum), showing up in only about 0.5% to 2% of cases. When it does appear, doctors have a special tool called a TRK inhibitor, which acts like a master key to turn that broken switch back off. But here is the big question: does this key work forever, or does the tumor eventually learn how to pick the lock?
This paper tells the story of a 38-year-old woman with advanced colorectal cancer who had exactly this rare broken switch, known as an NTRK1 gene fusion. Her medical journey began in July 2025 when she felt fullness in her upper abdomen. Scans revealed a tumor in her colon that had spread to her liver and lymph nodes. After a biopsy confirmed the cancer, doctors discovered she had the NTRK1-PLEKHA6 fusion, a specific type of broken switch, while her other common cancer genes were normal. Her first treatment, a standard combination of chemotherapy and a drug called cetuximab, didn't work well; her liver tumors actually grew. So, her doctors switched tactics and gave her a TRK inhibitor called larotrectinib, designed specifically to target her broken switch. Initially, this seemed like a victory: her liver tumors shrank, and her disease remained stable for 3.5 months. However, the victory was short-lived. Despite continuing the drug, her tumors began to grow again, and her tumor markers (chemical signals in the blood) skyrocketed.
The authors of this paper use this case to highlight a tricky reality: while TRK inhibitors are powerful, the response can be fleeting. In this specific patient, the drug worked for a while but then the cancer found a way to keep growing. The doctors tried adding more chemotherapy to the mix, but the patient's body couldn't handle it, and the cancer continued to progress. The paper suggests that the reason for this short-lived success might be linked to the specific type of fusion she had. The patient had a PLEKHA6-NTRK1 fusion. The authors point out that in previous studies, this specific combination of genes seemed to respond less dramatically than other types of fusions, often resulting in "stable disease" (where the tumor stops growing but doesn't shrink much) rather than a complete disappearance. They also note that the number of copies of the fusion gene didn't seem to change the outcome.
The story doesn't end with a failure, but with a call for a new strategy. The paper explains that when cancer stops responding to these drugs, it's often because the tumor has mutated again or found a different path to grow, like a thief finding a back door. To figure out what happened, the authors plan to take a new sample of the liver tumor to look for these new mutations. They suggest that if the tumor has changed the shape of the lock (a secondary mutation), a newer, stronger key (a second-generation TRK inhibitor) might be needed. If the tumor has opened a back door (activating a different pathway), a different combination of drugs might be required. This case serves as a reminder that while we have found a key that can open the door for some patients, we must remain ready to change our approach as the tumor tries to outsmart us. The goal is to move from simply controlling the disease to finding a way to cure it, but for now, the path requires constant vigilance and a willingness to adapt.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.